Clinical Study
Polymorphism of μ-Opioid Receptor Gene (OPRM1:c.118A>G) Might Not Protect against or Enhance Morphine-Induced Nausea or Vomiting
Table 1
The association between the severity of IVPCA morphine-induced side effects and genotype.
| | | Total () | Genotype | P value | | A/A () | A/G () | G/G () |
| | Nausea | Severe | 36 (27.9%) | 15 (26.8%) | 16 (28.1%) | 5 (31.3%) | 0.987 | | Mild | 45 (34.9%) | 19 (33.9%) | 21 (36.8%) | 5 (31.3%) | | None | 48 (37.2%) | 22 (39.3%) | 20 (35.1%) | 6 (37.5%) | | Vomiting | Severe | 28 (21.7%) | 11 (19.6%) | 14 (24.6%) | 3 (18.8%) | 0.910 | | Mild | 30 (23.3%) | 13 (23.2%) | 12 (21.1%) | 5 (31.3%) | | None | 71 (55.0%) | 32 (57.1%) | 31 (54.4%) | 8 (50.0%) | | Itching | Severe | 3 (2.3%) | 2 (3.6%) | 1 (1.8%) | 0 (0.0%) | 0.976 | | Mild | 11 (8.5%) | 5 (8.9%) | 5 (8.8%) | 1 (6.3%) | | None | 115 (89.1%) | 49 (87.5%) | 51 (89.5%) | 15 (93.8%) | | Dizziness | Severe | 10 (7.8%) | 5 (8.9%) | 4 (7.0%) | 1 (6.3%) | 0.672 | | Mild | 51 (39.5%) | 20 (35.7%) | 22 (38.6%) | 9 (56.3%) | | None | 68 (52.7%) | 31 (55.4%) | 31 (54.4%) | 6 (37.5%) |
|
|
